• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Revolution Medicines Inc.

    4/27/26 5:59:33 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RVMD alert in real time by email
    DEFA14A 1 d12857ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    REVOLUTION MEDICINES, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    SCAN TO VIEW MATERIALS & VOTE REVOLUTION MEDICINES, INC. VOTE BY INTERNET 700 SAGINAW DR. Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above REDWOOD CITY, CA 94063 Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/RVMD2026 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. This proxy is solicited on behalf of the Board of Directors of Revolution Medicines, Inc. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: V96593-P45570 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY REVOLUTION MEDICINES, INC. For All Withhold All Except For All To withhold authority to vote for any individual The Board of Directors recommends that you vote FOR the nominee(s), mark “For All Except” and write the election of the director nominees named in Proposal No. 1 of number(s) of the nominee(s) on the line below. the Proxy Statement; FOR the ratification of the appointment ! ! ! of PricewaterhouseCoopers LLP, as the independent registered public accounting firm, as described in Proposal No. 2 of the Proxy Statement; and FOR the approval, on a non-binding, advisory basis, of the Say-On-Pay proposal as described in Proposal No. 3 of the Proxy Statement. 1. To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected; Nominees: 01) Alexis Borisy For Against Abstain 02) Mark A. Goldsmith, M.D., Ph.D. 2. To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public ! ! ! accounting firm of the Company for its fiscal year ending December 31, 2026; and 3. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant ! ! ! to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”). NOTE: The proxies are authorized to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date


    LOGO

    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice, Proxy Statement and Annual Report on Form 10-K of Revolution Medicines, Inc. are available at www.proxyvote.com. V96594-P45570 REVOLUTION MEDICINES, INC. Annual Meeting of Stockholders June 18, 2026, 7:30 a.m. PDT This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Mark A. Goldsmith, M.D., Ph.D. and Jeffrey Cislini, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of REVOLUTION MEDICINES, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 7:30 a.m. PDT on June 18, 2026, at www.virtualshareholdermeeting.com/RVMD2026, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations. Continued and to be signed on reverse side

    Get the next $RVMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVMD

    DatePrice TargetRatingAnalyst
    5/22/2026$151.00Mkt Perform
    Bernstein
    5/18/2026$179.00Buy
    Truist
    3/16/2026Buy
    Jefferies
    2/27/2026$145.00Buy
    UBS
    11/18/2025$75.00Outperform
    Wolfe Research
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    10/21/2025$90.00Outperform
    Mizuho
    10/16/2025$85.00Buy
    Stifel
    More analyst ratings

    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

    REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results will be presented during a late-breaking Plenary Session (LBA5) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting at 3:21 p.m. CDT today and were published today in The New England Journal of Medicine. RA

    5/31/26 8:06:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

    REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. To listen to the live webcast, or access th

    5/21/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

    REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC). The promising Phase 1/2 findings provided important insights supporting initiation of the company's global, randomized Phase 3 registrational trial, RASolute 302. Revolution Medicines recently announced positive to

    5/6/26 6:00:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.

    SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    5/15/26 11:23:37 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Revolution Medicines Inc.

    10-Q - Revolution Medicines, Inc. (0001628171) (Filer)

    5/6/26 4:10:50 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Revolution Medicines, Inc. (0001628171) (Filer)

    5/6/26 4:05:17 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Revolution Medicines with a new price target

    Bernstein initiated coverage of Revolution Medicines with a rating of Mkt Perform and set a new price target of $151.00

    5/22/26 8:49:34 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Revolution Medicines with a new price target

    Truist resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $179.00

    5/18/26 8:36:12 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Revolution Medicines

    Jefferies resumed coverage of Revolution Medicines with a rating of Buy

    3/16/26 9:35:47 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    5/28/26 4:10:48 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Mancini Anthony exercised 3,120 shares at a strike of $33.62 and sold $413,129 worth of shares (3,120 units at $132.41) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    4/29/26 5:50:57 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Goldsmith Mark A

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    4/17/26 7:26:28 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

    REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. To listen to the live webcast, or access th

    5/21/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

    Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug AdministrationAACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibitionStrengthened financial position with financings totaling $2.2 billion in gross proceedsRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 06, 2026 (GLOBE N

    5/6/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

    4/29/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 6:30:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 9:26:21 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

    Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

    12/15/22 7:00:00 AM ET
    $GERN
    $MRNA
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

    REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

    7/13/22 7:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care